Day: March 14, 2026

The Annual General Meeting of Iceland Seafood International hf will be held on Tuesday 24 March 2026 at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavik, Iceland.  The meeting will be in Icelandic. Enclosed is the final agenda for the Annual General Meeting 2026 and final proposals. No changes have been made neither to the proposals nor the agenda since the meeting was convened. Information and documents for the Annual General Meeting can be found on the company’s website: Annual General Meeting (icelandseafood.com)AttachmentsISI_AGM_Notice to convene the AGM 2026ISI_AGM_Board Proposals 2026

New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered comparable adherence and outcomes between the first and second six-month period, indicating high accuracy and performance from a single sensor across an entire year GERMANTOWN, Md., March 14, 2026 (GLOBE NEWSWIRE) — Senseonics, a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces new data from a real-world evidence study which demonstrates the sustained performance and positive impact of Eversense 365 across the full one-year period. These findings were presented during an oral presentation...

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company’s Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes (“T2D”). “We are encouraged by the durability of icovamenib’s effect observed nine months post-dosing at Week 52,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “We believe that we now have in hand initial evidence of durable efficacy,...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – VANCOUVER, BC, March 13, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, announces that it has entered into a settlement agreement (the “Agreement”) with its former auditor (the “Auditor”) for settlement and termination of a Notice of Civil Claim filed by the Auditor in the Supreme Court of British Columbia (the “Claim”). Pursuant to the Agreement, the Company will pay the Auditor $65,000 in cash, payable in five equal instalments of $13,000 each, and will issue 1,917,967 common shares of the Company (the “Settlement Shares”) at a deemed price of $0.02 per Settlement Share, as approved by the Canadian Securities Exchange (the...